UK-based clinical artificial intelligence (AI) technology company Sensyne Health has named Cognizant and Agorai as its partners for the launch and commercialisation of its digital health software products in the US.
GDm-Health is a prescribed digital therapeutic software designed to manage gestational diabetes, while EDGE is a programme for the control of Chronic Obstructive Pulmonary Disease at home and Support-HF helps to monitor vital signs at home after heart failure.
GDm-Health will be the first to be launched out of the three products. It is currently in use by 15 National Health Service (NHS) trusts and is estimated to have helped around 6,100 patients in the UK to manage and control gestational diabetes.
The agreements with Cognizant, a US-based information technology, consulting and business process services in healthcare, do not include sharing of the UK patient data.
In collaboration with the University of Oxford, the products were first invented and developed within the NHS, then licensed to Sensyne Health.
Sensyne Health CEO Lord (Paul) Drayson said: “Cognizant and Agorai are excellent partners that will enable us to ensure that the full potential of these innovative products, first invented in the UK’s NHS, is realised in the US market.
“Following the appropriate regulatory approvals, Cognizant will provide these digital health applications to US health care providers and the commercial return made by Sensyne will be shared with the NHS.”
Financial returns made by Sensyne Health with the two firms will be shared with the NHS through Sensyne’s partnership model.
In October, Sensyne partnered up with Bayer to create AI-enabled radiology and imaging solutions.